Safety of long-term large doses of aspartame

A. S. Leon, D. B. Hunninghake, C. Bell, D. K. Rassin, T. R. Tephly

Research output: Contribution to journalArticle

60 Citations (Scopus)

Abstract

Safety of long-term administration of 75 mg/kg of aspartame per day was evaluated with the use of a randomized, double-blind, placebo-controlled, parallel-group design in 108 male and female volunteers aged 18 to 62 years. Subjects received either aspartame or placebo in capsule form three times daily for 24 weeks. No persistent changes over time were noted in either group in vital signs; body weight; results of standard laboratory tests; fasting blood levels of aspartame's constituent amino acids (aspartic acid and phenylalanine), other amino acids, and methanol; or blood formate levels and 24-hour urinary excretion of formate. There also were no statistically significant differences between groups in the number of subjects experiencing symptoms or in the number of symptoms per subject. These results further document the safety of the long-term consumption of aspartame at doses equivalent to the amount of aspartame in approximately 10 L of beverage per day.

Original languageEnglish (US)
Pages (from-to)2318-2324
Number of pages7
JournalArchives of Internal Medicine
Volume149
Issue number10
StatePublished - 1989

Fingerprint

Aspartame
formic acid
Safety
Placebos
Amino Acids
Vital Signs
Beverages
Phenylalanine
Aspartic Acid
Capsules
Methanol
Volunteers
Fasting
Body Weight

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Leon, A. S., Hunninghake, D. B., Bell, C., Rassin, D. K., & Tephly, T. R. (1989). Safety of long-term large doses of aspartame. Archives of Internal Medicine, 149(10), 2318-2324.

Safety of long-term large doses of aspartame. / Leon, A. S.; Hunninghake, D. B.; Bell, C.; Rassin, D. K.; Tephly, T. R.

In: Archives of Internal Medicine, Vol. 149, No. 10, 1989, p. 2318-2324.

Research output: Contribution to journalArticle

Leon, AS, Hunninghake, DB, Bell, C, Rassin, DK & Tephly, TR 1989, 'Safety of long-term large doses of aspartame', Archives of Internal Medicine, vol. 149, no. 10, pp. 2318-2324.
Leon AS, Hunninghake DB, Bell C, Rassin DK, Tephly TR. Safety of long-term large doses of aspartame. Archives of Internal Medicine. 1989;149(10):2318-2324.
Leon, A. S. ; Hunninghake, D. B. ; Bell, C. ; Rassin, D. K. ; Tephly, T. R. / Safety of long-term large doses of aspartame. In: Archives of Internal Medicine. 1989 ; Vol. 149, No. 10. pp. 2318-2324.
@article{4b1bf9b2931f4fa19937ccc53c1310cc,
title = "Safety of long-term large doses of aspartame",
abstract = "Safety of long-term administration of 75 mg/kg of aspartame per day was evaluated with the use of a randomized, double-blind, placebo-controlled, parallel-group design in 108 male and female volunteers aged 18 to 62 years. Subjects received either aspartame or placebo in capsule form three times daily for 24 weeks. No persistent changes over time were noted in either group in vital signs; body weight; results of standard laboratory tests; fasting blood levels of aspartame's constituent amino acids (aspartic acid and phenylalanine), other amino acids, and methanol; or blood formate levels and 24-hour urinary excretion of formate. There also were no statistically significant differences between groups in the number of subjects experiencing symptoms or in the number of symptoms per subject. These results further document the safety of the long-term consumption of aspartame at doses equivalent to the amount of aspartame in approximately 10 L of beverage per day.",
author = "Leon, {A. S.} and Hunninghake, {D. B.} and C. Bell and Rassin, {D. K.} and Tephly, {T. R.}",
year = "1989",
language = "English (US)",
volume = "149",
pages = "2318--2324",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "10",

}

TY - JOUR

T1 - Safety of long-term large doses of aspartame

AU - Leon, A. S.

AU - Hunninghake, D. B.

AU - Bell, C.

AU - Rassin, D. K.

AU - Tephly, T. R.

PY - 1989

Y1 - 1989

N2 - Safety of long-term administration of 75 mg/kg of aspartame per day was evaluated with the use of a randomized, double-blind, placebo-controlled, parallel-group design in 108 male and female volunteers aged 18 to 62 years. Subjects received either aspartame or placebo in capsule form three times daily for 24 weeks. No persistent changes over time were noted in either group in vital signs; body weight; results of standard laboratory tests; fasting blood levels of aspartame's constituent amino acids (aspartic acid and phenylalanine), other amino acids, and methanol; or blood formate levels and 24-hour urinary excretion of formate. There also were no statistically significant differences between groups in the number of subjects experiencing symptoms or in the number of symptoms per subject. These results further document the safety of the long-term consumption of aspartame at doses equivalent to the amount of aspartame in approximately 10 L of beverage per day.

AB - Safety of long-term administration of 75 mg/kg of aspartame per day was evaluated with the use of a randomized, double-blind, placebo-controlled, parallel-group design in 108 male and female volunteers aged 18 to 62 years. Subjects received either aspartame or placebo in capsule form three times daily for 24 weeks. No persistent changes over time were noted in either group in vital signs; body weight; results of standard laboratory tests; fasting blood levels of aspartame's constituent amino acids (aspartic acid and phenylalanine), other amino acids, and methanol; or blood formate levels and 24-hour urinary excretion of formate. There also were no statistically significant differences between groups in the number of subjects experiencing symptoms or in the number of symptoms per subject. These results further document the safety of the long-term consumption of aspartame at doses equivalent to the amount of aspartame in approximately 10 L of beverage per day.

UR - http://www.scopus.com/inward/record.url?scp=0024439427&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024439427&partnerID=8YFLogxK

M3 - Article

VL - 149

SP - 2318

EP - 2324

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 10

ER -